Navigation Links
To evade chemotherapy, some cancer cells mimic stem cells
Date:9/19/2007

ATLANTA - Anti-cancer treatments often effectively shrink the size of tumors, but some might have an opposite effect, actually expanding the small population of cancer stem cells believed to drive the disease, according to findings presented today in Atlanta, Georgia at the American Association for Cancer Researchs second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.

Our experiments suggest that some treatments could be producing more cancer stem cells that then are capable of metastasizing, because these cells are trying to find a way to survive the therapy, said one of the studys investigators, Vasyl Vasko, M.D. Ph.D., a pathologist at the Uniformed Services University of the Health Sciences in Bethesda, Md.

This may help explain why the expression of stem cell markers has been associated with resistance to chemotherapy and radiation treatments and poor outcome for patients with cancers including prostate, breast and lung cancers, Dr. Vasko said. That tells us that understanding how to target these markers and these cells could prove useful in treating these cancers.

The cancer stem cell markers include Nanog and BMI1, both of which contribute to stem cells defining ability to renew themselves and differentiate into different cell types, Dr. Vasko said. These same molecules are found in embryonic stem cells.

Researchers have recently debated the notion that some therapies are not capable of eradicating cancer because they do not target the cancer stem cells responsible for tumor development. To test this hypothesis, Dr. Vasko, along with scientists from the CRTRC Institute for Drug Development in San Antonio and from the Johns Hopkins University, set out to measure both stem cells markers and tumor volume before and after treatment in a mouse model.

They selected a rare form of cancer, mesenchymal chondrosarcoma (MCS), which has not been well described and for which there is no effective treatment. The researchers first determined that Nanog and BMI1 stem cell markers were more highly expressed in metastatic tumors compared to primary tumors. This suggests that expression of the marker plays some role in development of metastasis, Dr. Vasko said.

They then applied various therapies - from VEGF inhibitors such as Avastin to the proteasome inhibitor Velcade - in mice implanted with human MSC, and analyzed the effects on tumors. Some of the treatments seemed to work, because they led to a dramatic decrease in the size of the tumors, Dr. Vasko said. But analysis of stem cell expression before and after treatment revealed that even as some anti-cancer treatments shrank tumors, they increased expression of Nanog and BMI1. These treatments were not enough to completely inhibit tumor growth, and the cancer stem cell markers were still present, Dr. Vasko said.

Use of the agents Velcade and Docetaxel led to the most significant increase in stem cell markers within the treated tumor, while ifosfamide and Avastin inhibited expression of the markers in this cancer subtype.

We hypothesize that the tumor escapes from chemotherapy by induction of stem cell marker expression, he said. The small number of cells that survive the treatment could then generate another tumor that metastasizes.

Dr. Vasko doesnt know how this happens, but theorizes that dying cells could secrete a lot of factors that induce expression of stem cell markers in other cancer cells. I think they are trying to survive and they use a mechanism from their experience of embryonic life.


'/>"/>

Contact: Greg Lester
267-646-0554
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Herpes Infects Cornea, Evades Immune Cells
2. Researchers Discover How Cancer Evades the Immune System
3. Radiation And Chemotherapy, A Better Option For Head And Neck Cancer
4. Watchdog to Be Set on Oral Chemotherapy, Warns Experts
5. Fibroids unlikely to Turn Cancerous
6. Virus Level could Predict Cervical Cancer Risk
7. Cancer Doctors Okays Controversial Prostate Therapy
8. Potential New Cancer Gene Identified
9. Vitamin B12 can help in detecting cancers
10. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
11. Consensus on "Combination Therapy" for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... 02, 2016 , ... Advanced Inc., a leading provider of travel therapy and ... to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously ... financial and operational leadership experience to Advanced Inc. He began his career in finance ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... N.J. , Dec. 3, 2016  Findings ... and safety of CTL019, an investigational chimeric antigen ... (r/r) pediatric and young adult patients with B-cell ... during an oral session at the 58th American ... December 3, 4:00-5:30 p.m.). The global Phase II ...
(Date:12/2/2016)... bioLytical Laboratories, un líder mundial en test rápidos de ... Self Test , a los miembros de la Kenya Pharmaceutical Association. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton ...
(Date:12/2/2016)... According to the latest market report ... Automated Endoscope Reprocessors: Single Basin Automated Endoscope Reprocessors Product Type ... and 2024 " the global automated endoscope reprocessors market was valued at US$ ... a CAGR of 7.2% during an eight-year forecast period 2016-2024, ... 2024. ...
Breaking Medicine Technology: